secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-03-06T23:59:59+00:00
Accession:  0001193125-26-096734
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix Therapeutics ups ATM equity offering capacity to $413.65M
---------------------------------------------------------------

- Amendment No. 3 to Equity Distribution Agreement with Piper Sandler dated March 6, 2026.
- Maximum aggregate gross offering price of common stock increased from $300M to $413.65M.
- Shares offered at-the-market from time to time; prospectus supplement filed same day.
- Proceeds not specified; prior ATM sales included in the increased limit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000119312526096734/0001193125-26-096734-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000119312526096734/d32105d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-096734

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer